Tamoxifen

Routes
Oral (PO)
Half-Life (t½)
PO: 4d
Formula
C26H29NO
Molecular Weight
371.51 g/mol
PubChem CID
2733526
Aliases
Nolvadex, ICI 46474

Pharmacological Mechanism

Triphenylethylene SERM. Tissue-selective ER agonism/antagonism: antagonist in breast (anti-proliferative, primary indication), partial agonist in bone (protective) + endometrium (hyperplasia / cancer risk) + liver (lipid + clotting-factor effects). Activity driven primarily by the CYP2D6-derived metabolite endoxifen (~100× ER affinity vs parent). In men: blocks hypothalamic ER-mediated negative feedback → raises LH/FSH → testicular testosterone — rationale for PCT after AAS cycles and off-label treatment of gynaecomastia.

Half-Life & Elimination Curve (PO: 4d)

100%50%25%12.5%0%0h0×t½4d1×t½8d2×t½12d3×t½16d4×t½20d5×t½0×t½ (0h): 100% remaining (~13.9 µg/L)1×t½ (4d): 50% remaining (~6.95 µg/L)2×t½ (8d): 25% remaining (~3.47 µg/L)3×t½ (12d): 12.5% remaining (~1.74 µg/L)4×t½ (16d): 6.3% remaining (~0.868 µg/L)5×t½ (20d): 3.1% remaining (~0.434 µg/L)
Plasma (PO)t½ Decay (4d)Effect Site (ke0)
  • 0×t½0h100% (13.9 µg/L)
  • 1×t½4d50% (6.95 µg/L)
  • 2×t½8d25% (3.47 µg/L)
  • 3×t½12d12.5% (1.74 µg/L)
  • 4×t½16d6.3% (0.868 µg/L)
  • 5×t½20d3.1% (0.434 µg/L)
Elimination t½4d (PO)
Rate Constant (ke)0.00722 h⁻¹
Time to Peak (Tmax)3.85h
Est. Peak (Cmax)13.9 µg/L
Clearance (CL)10.1 L/h
97% Washout (5×t½)20d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Interactions

Chemical Structure & Identifiers

References